Abstract
Chagas disease is caused by infection with the protozoan pathogen, Trypanosoma cruzi. The only approved therapeutics for treating Chagas disease are two nitroheterocydic compounds (benznidazole and nifurtimox) that are suboptimal due to poor curative activity for chronic Chagas disease and high rates of adverse drug reactions. Sterol 14-demethylase inhibitors include azole antifungal drugs such as ketoconazole, fluconazole, itraconazole, and others. The first reports of potent activity of azole antifungal drugs against Trypanosoma cruzi came out about 25 years ago. Since then, a sizeable literature has accumulated on this topic. Newer triazole compounds such as posaconazole and D0870 have been shown to be effective at curing mice with chronic Trypanosoma cruzi infection. Small clinical studies with ketoconazole or itraconazole in humans with chronic Chagas disease have not demonstrated significant curative activity. However, there is good reason for optimism that newer compounds with greater potency and improved pharmacokinetic properties might be more efficacious. Data have been published demonstrating synergistic activity of azole drugs with various other compounds, indicating that combination chemotherapy may be an effective strategy as this field moves ahead. In light of the near absence of adequate therapeutics for curing patients with chronic Chagas disease, additional effort to develop better drugs needs to be a priority.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Docampo R, Moreno SN, Turrens JF et al. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol Biochem Parasitol 1981; 3:169–80.
World Health Organization. Control of Chagas’ disease. WHO Tech Rep Ser 1991; 811:1–93.
Eisen H, Petry K, Van Voorhis WC. The origin of autoimmune pathology associated with Trypanosoma cruzi infection. In: Van Der Ploeg LHT, Cantor CR, Voegel HJ, eds. Immune Recognition and Evasion: Molecular Aspects of Host-Parasite Interaction. London: Academic Press Inc., 1990:91–103.
Viotti R, Vigliano C, Armenti H et al. Treatment of chronic Chagas’ disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up. Am Heart J 1994; 127:151–62.
Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol 2003; 19:495–501.
Sosa ES, Segura EL, Ruiz AM et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg 1998; 59:526–29.
Pan American Health Organization/World Health Organization. Etiological treatment for Chagas disease. Rev Pat Trop 1998; 28:247–79.
Daum G, Lees ND, Bard M et al. Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast 1998; 14:1471–510.
Lamb DC, Kelly DE, Waterman MR et al. Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents. Yeast 1999; 15:755–63.
Fischer RT, Stam SH, Johnson PR et al. Mechanistic studies of lanosterol 14 alpha-methyl demethylase: Substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme. J Lipid Res 1989; 30:1621–32.
Rozman D, Stromstedt M, Waterman MR. The three human cytochrome P450 lanosterol 14 alpha-demethylase (CYP51) genes reside on chromosomes 3, 7, and 13: Structure of the two retrotransposed pseudogenes, association with a line-1 element, and evolution of the human CYP51 family. Arch Biochem Biophys. 1996; 333:466–74.
Lepesheva GI, Nes WD, Zhou W et al. CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochem 2004; 43:10789–99.
Podust LM, Yermalitskaya LV, Lepesheva GI et al. Estriol bound and ligand-free structures of sterol 14alpha-demethylase. Structure (Camb.) 2004; 12:1937–45.
Hucke O, Gelb MH, Verlinde CL et al. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 2005; 48:5415–18.
Walker KA, Kertesz DJ, Rotstein DM et al. Selective inhibition of mammalian lanosterol 14 alpha-demethylase: A possible strategy for cholesterol lowering. J Med Chem 1993; 36:2235–37.
Vanden Bossche H, Marichal P, Gorrens J et al. Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells. Pestic Sci 1987; 21:289–306.
Lewis DF. 57 varieties: The human cytochromes P450. Pharmacogenomics 2004; 5:305–18.
Pont A, Williams PL, Azhar S et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142:2137–40.
Pont A, Williams PL, Loose DS et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 1982; 97:370–72.
Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 1986; 7:409–20.
Korn ED, Von Brand T, Tobie EJ. The sterols of Trypanosoma cruzi and Crithidia fasciculata. Comp Biochem Physiol 1969; 30:601–10.
Docampo R. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Molec Biochem Parasitol 1981; 3:169–80.
Beach DH, Goad LJ, Holz Jr GG. Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi epimastigotes. Biochem Biophys Res Commun 1986; 136:851–56.
Goad LJ, Berens RL, Marr JJ et al. The activity of ketoconazole and other azoles against Trypanosoma cruzi: Biochemistry and chemotherapeutic action in vitro. Molec Biochem Parasitol 1989; 32:179–90.
Urbina JA, Vivas J, Visbal G et al. Modification of the sterol composition of Trypanosoma (Schizotrypanum) cruzi epimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol Biochem Parasitol 1995; 73:199–210.
Lazardi K, Urbina JA, de Souza W. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1990; 34:2097–105.
Liendo A, Visbal G, Piras MM et al. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol Biochem Parasitol 1999; 104:81–91.
Liendo A, Lazardi K, Urbina JA. In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi. J Antimicrob Chemother 1998; 41:197–205.
Urbina JA, Lazardi K, Aguirre T et al. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1988; 32:1237–42.
Urbina JA, Payares G, Contreras LM et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo studies. Antimicrob Agents Chemother 1998; 42:1771–77.
Buckner FS, Joubert BM, Boyle SM et al. Cloning and analysis of Trypanosoma cruzi lanosterol 14α-demethylase. Mol Biochem Parasitol 2003; 132:75–81.
Lepesheva GI, Zaitseva NG, Nes WD et al. CYP51 from Trypanosoma cruzi: A phyla-specific residue in the B’ helix defines substrate preferences of sterol 14alpha-demethylase. J Biol Chem 2006; 281:3577–85.
Buckner F, Yokoyama K, Lockman J et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci USA 2003; 100:15149–53.
McCabe R. Failure of ketoconazole to cure chronic murine Chagas' disease. J Infect Dis 1988; 158:1408–09.
Urbina JA, Payares B, Molina J et al. Cure of short-and long-term experimental Chagas’ disease using D0870. Science 1996; 273:969–71.
Moreira AA, de Souza HB, Amato-Neto V et al. Evaluation of the therapeutic activity of itraconazole in chronic infections, experimental and human, by Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 1992; 34:177–80.
Urbina JA, Payares G, Sanoja C et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003; 21:27–38.
Urbina JA, Payares G, Sanoja C et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 2003; 21:39–48.
Corrales M, Cardozo R, Segura MA et al. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas’ disease. Antimicrob Agents Chemother 2005; 49:1556–60.
Brener Z. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz 1993; 88:149–53.
Toledo MJ, Bahia MT, Veloso VM et al. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes. J Antimicrob Chemother 2004; 53:1045–53.
Guedes PM, Urbina JA, de Lana M et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother 2004; 48:4286–92.
Araujo MS, Martins-Filho OA, Pereira ME et al. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas’ disease. J Antimicrob Chemother 2000; 45:819–24.
Maldonado RA, Molina J, Payares G et al. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas’ disease. Antimicrob Agents Chemother 1993; 37:1353–59.
Benaim G, Sanders JM, Garcia-Marchan Y et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 2006; 49:892–99.
Apt W, Aguilera X, Arribada A et al. Treatment of chronic Chagas’ disease with itraconazole and allopurinol. Am J Trop Med Hyg 1998; 59:133–38.
Apt W, Arribada A, Zulantay I et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: The results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 2005; 99:733–41.
Buckner FS, Verlinde CLMJ, La Flamme AC et al. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob Agents Chemother 1996; 40:2592–97.
McCabe RE, Remmington JS, Araujo FG. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg 1986; 35:280–84.
McCabe RE, Remington JS, Araujo FG. Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J Infect Dis 1984; 150:594–601.
Urbina JA, Lazardi K, Marchan E et al. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo studies. Antimicrob Agents Chemother 1993; 37:580–91.
Urbina JA, Lira R, Visbal G et al. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 2000; 44:2498–502.
Campos R, Amato NV, Moreira AA et al. Evaluation of the therapeutic activity of fluconazole in acute experimental infection caused by Trypanosoma cruzi. Rev Hosp Clin Fac Med Sao Paulo 1992; 47:174–75.
Molina J, Martins-Filho O, Brener Z et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000; 44:150–55.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Buckner, F.S. (2008). Sterol 14-Demethylase Inhibitors for Trypanosoma cruzi Infections. In: Majumder, H.K. (eds) Drug Targets in Kinetoplastid Parasites. Advances In Experimental Medicine And Biology, vol 625. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77570-8_6
Download citation
DOI: https://doi.org/10.1007/978-0-387-77570-8_6
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-77569-2
Online ISBN: 978-0-387-77570-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)